Efficacy and Safety of Adding an Agent to Bevacizumab/Taxane Regimens for the First-Line Treatment of Her2-Negative Patients With Locally Recurrent or Metastatic Breast Cancer: Results From Seven Randomized Controlled Trials
OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s103954
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2016
Authors
Publisher
Informa UK Limited